Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURONTIN vs FINTEPLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Postherpetic neuralgia,Partial onset seizures (adjunctive therapy),Restless legs syndrome (off-label),Neuropathic pain (off-label),Diabetic peripheral neuropathy (off-label),Fibromyalgia (off-label),Generalized anxiety disorder (off-label)
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older,Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 m L/min.
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Gabapentin does not undergo hepatic metabolism; it is excreted unchanged in urine. No involvement of cytochrome P450 enzymes.
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 to its active metabolite norfenfluramine. Norfenfluramine is further metabolized by CYP2D6 and other enzymes.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
<3% bound to plasma proteins (negligible).
Approximately 55% bound to plasma proteins, primarily albumin.
Volume of distribution is 0.8 L/kg (57 L in a 70 kg adult), indicating distribution into total body water.
Apparent volume of distribution (Vd/F) approximately 2.5–3.5 L/kg, suggesting extensive extravascular distribution.
Oral bioavailability is approximately 60% (30–90% with interindividual variability); decreases with higher doses due to saturable absorption; not affected by food.
Oral bioavailability approximately 80% (relatively high first-pass metabolism: moderate).
For Cr Cl 30-59 m L/min: 200-700 mg twice daily. For Cr Cl 15-29 m L/min: 200-700 mg once daily. For Cr Cl <15 m L/min: 100-300 mg once daily. Hemodialysis: loading dose 300-400 mg, then 200-300 mg after each 4-hour dialysis session.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No specific dose adjustment guidelines; pharmacokinetics unchanged in hepatic impairment per manufacturer.
Mild hepatic impairment (Child-Pugh A): maximum dose 11 mg/day. Moderate to severe (Child-Pugh B or C): not recommended.
For epilepsy (ages 3-12): initial 10-15 mg/kg/day in 3 divided doses, titrate over 3 days to effective dose, maintenance 25-35 mg/kg/day in 3 divided doses; maximum 50 mg/kg/day. For postherpetic neuralgia: not indicated.
For patients weighing 10-50 kg: initial 0.05 mg/kg twice daily; titrated to 0.1 mg/kg twice daily (target), may increase to 0.2 mg/kg twice daily (max). For patients weighing ≥50 kg: same as adult dosing (max 16 mg/day). Not established for weight <10 kg.
Initiate at lower dose (e.g., 100-300 mg/day) and titrate slowly; monitor for dizziness, sedation, and renal function; adjust dose based on creatinine clearance.
No specific dose adjustment; start at low end of dosing range due to greater frequency of decreased hepatic/renal function and concomitant disease.
None.
Valvular heart disease and pulmonary arterial hypertension: FINTEPLA is associated with valvular heart disease (e.g., mitral and aortic regurgitation) and pulmonary arterial hypertension. Patients must undergo echocardiography before starting treatment, at 3 months, and every 6-12 months thereafter.
Respiratory depression: risk increased with opioid coadministration or in elderly patients,Central nervous system effects: dizziness, somnolence, ataxia,Increased seizure frequency with abrupt withdrawal,Suicidal behavior and ideation,Anaphylaxis and angioedema,Drug reaction with eosinophilia and systemic symptoms (DRESS),Pancreatitis,Abrupt discontinuation may precipitate status epilepticus in patients with seizures
Valvular heart disease and pulmonary arterial hypertension: monitor with echocardiography,Increased intraocular pressure: caution in patients with glaucoma,Suicidal thoughts and behavior: monitor for worsening depression and suicidality,Dizziness, somnolence, and fatigue: may impair ability to drive or operate machinery,Decreased appetite and weight loss: monitor weight, especially in pediatric patients,Potential for abuse and dependence: controlled substance (Schedule IV)
Hypersensitivity to gabapentin or any component of the formulation
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI,Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome,Hypersensitivity to fenfluramine or any component of the formulation
No significant food interactions. Avoid alcohol due to additive CNS depression.
Avoid grapefruit and grapefruit juice as they are CYP1A2 inhibitors and may increase fenfluramine exposure. No other significant food interactions reported.
First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third trimester: Risk of fetal growth restriction, preterm birth, and neonatal withdrawal symptoms (e.g., feeding difficulties, irritability) after in utero exposure.
FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In animal studies, fenfluramine caused embryofetal mortality and structural abnormalities at clinically relevant doses. During the second and third trimesters, exposure may lead to fetal growth restriction and neurodevelopmental effects. Use during pregnancy is contraindicated unless no safer alternative exists.
Gabapentin is excreted into human milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure (relative infant dose <2% of maternal weight-adjusted dose). Monitor infant for drowsiness, poor feeding, and gastrointestinal disturbances. Benefit of breastfeeding should be weighed against potential risks.
Fenfluramine is excreted into human breast milk; the milk-to-plasma (M/P) ratio is approximately 0.5. Based on limited data, the relative infant dose is estimated to be <10% of the maternal weight-adjusted dose. However, prolonged exposure may cause adverse effects in the infant (e.g., irritability, feeding difficulties). Breastfeeding is not recommended during FINTEPLA therapy due to potential for serious adverse reactions.
Increased clearance of gabapentin during pregnancy may require dose adjustments. Monitoring of clinical response and adverse effects is recommended. Consider gradual dose reduction postpartum to pre-pregnancy levels. No established dosing guidelines; individualize based on therapeutic response and tolerability.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic studies. However, physiological changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may necessitate therapeutic drug monitoring and dose titration. Use lowest effective dose and consider alternative agents if possible.
Titrate slowly to reduce CNS depression risk. Reduce dose in renal impairment (Cr Cl <60). Drug of choice for postherpetic neuralgia. Gabapentin is not effective for acute pain. Avoid abrupt discontinuation to prevent withdrawal. Use with caution with opioids due to respiratory depression risk.
FINTEPLA (fenfluramine) is indicated for seizures associated with Dravet syndrome. Monitor for valvular heart disease and pulmonary arterial hypertension due to serotonergic effects; obtain baseline and periodic echocardiograms. Titrate slowly to minimize appetite suppression and weight loss. Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs due to risk of serotonin syndrome. Dose adjustment required in hepatic impairment.
May cause dizziness and drowsiness; avoid driving until effects known.,Take with or without food; avoid alcohol.,Do not stop suddenly; taper under doctor guidance.,May take time to work; adhere to prescribed dosing schedule.,Report any signs of allergic reaction, mood changes, or suicidal thoughts.
Take exactly as prescribed; do not stop abruptly as withdrawal may increase seizure frequency.,Common side effects include decreased appetite, weight loss, diarrhea, and fatigue.,Report any signs of heart problems such as shortness of breath, chest pain, or swelling of ankles.,Avoid grapefruit and grapefruit juice during treatment as it may increase drug levels.,Women of childbearing potential should use effective contraception due to potential fetal harm.,Do not drive or operate heavy machinery until you know how the medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURONTIN vs FINTEPLA, answered by our medical review team.
NEURONTIN is a Antiepileptic that works by Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.. FINTEPLA is a Antiepileptic that works by Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURONTIN and FINTEPLA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURONTIN is: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.. The standard adult dose of FINTEPLA is: 0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURONTIN and FINTEPLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURONTIN is classified as Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third . FINTEPLA is classified as Category C. FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In ani. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.